Business Context and Reporting Period
This Form 6-K filing is submitted by I-Mab (not Novabridge Biosciences) for the month of September 2025. The report announces an Extraordinary General Meeting of Shareholders scheduled for October 24, 2025, at 10:00 a.m. local time in Washington, D.C.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely as a notice of a shareholder meeting and does not contain financial performance data.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this filing.
Guidance, Outlook, and Corporate Actions
- Shareholder Meeting: An Extraordinary General Meeting will be held on October 24, 2025.
- Location: Offices of Kirkland & Ellis LLP, 1301 Pennsylvania Avenue, N.W., Washington, DC 20004.
- Materials: Proxy statements, notices, and voting cards are attached as exhibits and available on the company website.
- Incorporation by Reference: The filing is incorporated into various Registration Statements on Form F-3 and Form S-8.
Key Facts for Investor Verification
- Verify the specific agenda items for the October 24, 2025, Extraordinary General Meeting in the attached Proxy Statement (Exhibit 99.1).
- Confirm the company name is I-Mab, as the input metadata reference to "Novabridge Biosciences" appears inconsistent with the filing content.
- Review the attached exhibits for voting instructions and proxy forms for ADS holders.
- Note that this filing contains no financial results; investors should refer to recent Form 20-F or quarterly reports for financial data.